WallStSmart
BMY

Bristol-Myers Squibb Company

NYSE: BMY · HEALTHCARE · DRUG MANUFACTURERS - GENERAL

$57.59
-1.15% today

Updated 2026-04-29

Market cap
$119.87B
P/E ratio
16.97
P/S ratio
2.49x
EPS (TTM)
$3.46
Dividend yield
4.22%
52W range
$41 – $62
Volume
11.8M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Bristol-Myers Squibb Company (BMY) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$57.59
Consensus
$61.81
+7.33%
2030 Target
$286.08
+396.75%
DCF
$87.81
+31.75% MoS
16 analysts:
3 Buy8 Hold1 Sell

Management guidance

No specific CEO revenue targets found in provided data. Latest consensus shows 2026 revenue of $47.57B (down 1.29% YoY) and 2027 revenue of $46.60B (down 2.04% YoY). Management has not provided explicit guidance beyond 2027 in available materials.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$476.80
$50.5B Rev × 20x P/S
Base case (2030)
$286.08
$50.5B Rev × 12x P/S
Bear case (2030)
$190.72
$50.5B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$45.0B$48.3B$48.2B$47.6B$46.6B$47.2B$48.8B$50.5B
Revenue growth—7.3%-0.2%-1.3%-2.0%1.3%3.4%3.5%
EPS$7.39$1.14$6.15$6.33$6.19$6.50$6.85$7.20
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$268.20$262.24$268.20$274.16$286.08

Catalysts & risks

Growth catalysts
+ Positive Phase 3 SCOUT-HCM trial data for Camzyos (cardiac myosin inhibitor) in adolescents with obstructive hypertrophic cardiomyopathy—label expansion potential
+ FDA approval for Sotyktu expansion into psoriatic arthritis—broadens immunology franchise
+ Janux Therapeutics $35M milestone payment and ongoing tumor-activated therapy collaboration—validates R&D pipeline
+ Multiple Phase 3 wins in oncology (SUCCESSOR-2 in multiple myeloma, iza-bren in triple-negative breast cancer)—supports growth narrative
+ Patent cliff mitigation through new drug launches offsetting legacy drug declines (Eliquis, Opdivo exclusivity losses post-2026)
Key risks
- Patent expirations on blockbuster drugs Eliquis and Opdivo beginning 2026-2027—material revenue headwinds
- Trump administration tariff threats (up to 100%) on branded drugs unless price deals struck—threatens margin expansion and could compress revenues
- Negative revenue trend: -0.22% (2025), -1.29% (2026E), -2.04% (2027E)—structural decline in legacy portfolio not yet offset by new launches
- Legal dispute with former Celgene shareholders—contingent liability and distraction from core operations
- High debt leverage (Debt/Eq 2.55)—limits financial flexibility for M&A and R&D acceleration
- Insider selling signal (EVP David Elkins sold 30K shares in Q4; Trust Co. of Toledo reduced stake by 35%)—potential negative sentiment indicator

Methodology

Bristol-Myers Squibb Company's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 16 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 6, 2026.